| INTRODUCTION
Colorectal cancer (CRC) is a leading cancer globally in terms of both incidence and cancer-related mortality. 1 Hepatic metastatic disease from CRC is the main driver in terms of prognosis for these patients.
Twenty to 25% of patients will have synchronous hepatic metastases at diagnosis, and 60% will acquire liver metastases if they develop metastatic disease. 2 Several biomarkers have been identified as significant prognostic factors, including Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status, lactate dehydrogenase (LDH) level, and carcinoembryonic antigen (CEA) level.
KRAS is a gene involved in cell proliferation and survival and is mutated in approximately 40% of colorectal tumors, causing cancer cell growth. 3, 4 Studies have found that patients with KRAS mutated tumors have a lower recurrence free survival and lower overall survival (OS) rate compared to patients with wild-type tumors. 3, [5] [6] [7] LDH is a metabolic enzyme that catalyzes the conversion of pyruvate to lactate under anaerobic conditions and is over-produced in cancer cells. 8 Several studies have demonstrated a negative association between elevated LDH and OS. [9] [10] [11] CEA is a glycoprotein involved in cell adhesion, immunity, and apoptosis. 12 In healthy adults, CEA is produced in very low serum levels, however CEA production increases in patients with cancer. 13 CRC patients with abnormal CEA values have been shown to have lower OS compared to patients with normal CEA values. 9, 13 While there are multiple studies assessing the prognostic role of these biomarkers individually in CRC, there is a dearth of available data on the interdependence between these three important biomarkers. Baseline values were taken from the day initiating HAI treatment. >200 ng/mL) and LDH (≤200 vs. >200 U/L). 15 We also conducted a landmark analysis using complete hepatic liver resection 12 months as a pre-defined landmark time in order to examine the effect of resection on survival outcomes. 16 The landmark analysis attempts to account for the inherent bias in comparing patients with favorable responses (conversion to resection) to those with less favorable responses. Patients who had less than 12-month follow-up times were excluded from landmark analysis.
All P values were based on two-tailed statistical analysis and P < 0.05 was considered to indicate statistical significance. All analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC), and R (v 3.1.1) or R version 3.1.1.
| RESULTS
One hundred and ninety-three patients treated with HAI and systemic chemotherapy from 2002 to 2013 who had available KRAS mutational status with baseline CEA and LDH values were evaluated. One hundred twenty-one patients had hepatic-only disease prior to HAI treatment start while 72 patients had hepatic and extra-hepatic disease at baseline. In patients with hepatic-only disease (n = 121), 83 patients had tumors with KRAS WT while 38 patients had KRAS MUT. Nine patients had a BRAF mutation. In terms of baseline characteristics, a significantly higher proportion of patients with KRAS MUT had rightsided tumors, while KRAS WT patients more commonly had left sided and rectal tumors (P < 0.01, Table 1 ).
In the patients with extra-hepatic disease (n = 72), 39 patients had KRAS WT tumors while 33 patients were KRAS MUT. Three patients had a BRAF mutation. There was no significant difference in baseline patient characteristics related to KRAS status in this patient group (Table 2) .
| Overall survival
In patients with hepatic-only disease (n = 121), median follow-up was 41.5 months and median OS was 54.7 months (95%CI: 37.4-75 months). By univariate analysis, patients with KRAS WT tumors had a median OS of 68.3 months versus 30.7 months for KRAS MUT (P = 0.034). Patients with LDH ≤200 or >200 U/L had a median OS of 76.6 months versus 37.2 months, respectively (P = 0.041, Table 3 ).
Patients with CEA ≤200 or >200 ng/mL had a median OS of 60.2 months versus 33.3 months, respectively (P = 0.152). Patients receiving systemic chemotherapy with an oxaliplatin-regimen had a higher median survival than those receiving an irinotecan-regimen with HAI therapy (P = 0.086). In the multivariate model, KRAS MUT (P = 0.047), LDH >200 U/L (P = 0.015), and prior chemotherapy (P = 0.013) were significant for a lower OS while hepatic resection was significant for a higher survival (P = 0.026, MUT/LDH >200), patients who were KRAS WT with LDH ≤200 U/L had a significantly improved survival compared to the other three groups (log-rank test P = 0.021, Fig. 1 ). In similar analyses, there were no significant differences when evaluating OS by KRAS status and baseline CEA values (log-rank test P = 0.054) or by the combination of CEA and LDH values (log-rank test P = 0.088).
Among patients with hepatic-only disease (n = 121), 53 patients achieved liver resection after treatment. Cumulative incidence of resection by 12 months was 35% (95%CI: 26-44%). The cumulative incidence of liver resection was similar between KRAS WT versus MUT (39% versus 27%, respectively, P = 0.31). Among the 53 patients with liver resection, only two patients had CEA >200 ng/mL, and 45%
had LDH ≤200 versus 28% with LDH >200 U/L (P = 0.015). There was a significant improvement in survival for those patients who achieved a liver resection by 12 months (P = 0.003, Fig. 2 ).
In the extra-hepatic disease group (n = 72), median OS was 32.2 CEA >200 ng/mL (P = 0.003) and LDH >200 U/L (P = 0.003) were associated with lower survival (Table 5 ). KRAS mutational status was not significantly associated with OS (P = 0.256). In the multivariate model (Table 6 ), LDH >200 negatively impacted OS (HR: 3.8 [95%CI:
months (95%CI: 17.3-38.8 months). By univariate analysis, baseline
1.1-13.5], P = 0.035) while CEA >200 had borderline significance (HR: Among patients who presented with extra-hepatic disease prior to HAI therapy, twelve patients achieved liver resection, with a cumulative incidence of liver resection of 15.5% (95%CI: 7-24%). Liver resection was similar between KRAS WT and MUT (18.5% vs. 12.1%, P = 0.30), between CEA ≤200 or >200 ng/mL (17% vs. 10%, P = 0.39) and between LDH ≤200 or >200 U/L, respectively (14% vs. 16%, P = 0.67).
| Progression free survival
Median PFS for patients with hepatic-only disease (n = 121) was 10 months (95%CI: 9-12 months). By univariate analysis, elevated LDH was the only biomarker to influence PFS. Median PFS for LDH ≤200 versus >200 U/L was 13 versus 9 months, respectively (P = 0.018).
KRAS mutational status and CEA were not significant (P = 0.054 and P = 0.269, respectively). Prior chemotherapy before commencement of HAI negatively impacted PFS, with a median PFS of 14.7 months in patients with no previous chemotherapy versus 8.5 months for patients with previous therapy (P < 0.001). By multivariate analysis, prior chemotherapy and LDH >200 U/L remained significant (P < 0.001). When evaluating the interaction between KRAS status and baseline LDH in terms of PFS, there was no significant interaction (P = 0.986). However, when evaluating the combination of KRAS and baseline LDH as a single variable with four categories, KRAS WT patients with LDH ≤200 U/L had a superior PFS (log-rank test P = 0.018, Supplemental Fig. S4 ). There were no significant differences when evaluating PFS by KRAS status and CEA (P = 0.091), or a combination of baseline CEA and LDH values (P = 0.057).
| Patterns of tumor progression
Patterns of disease progression were evaluated in patients with hepatic-only disease (n = 121). Lung metastases developed in 52.9%
(n = 64), nodal metastases in 49.6% (n = 60), abdominal metastases in Among the subset of patients with lung metastases, 64% had baseline LDH >200 U/L, 34% KRAS MUT, and 9% CEA >200 ng/mL. In patients with nodal metastases, 38% had a baseline LDH >200 U/L, 33% KRAS MUT, and 13% CEA >200 ng/mL. Among the patients with abdominal metastases, 43% had baseline LDH >200 U/L, 35% KRAS MUT, and 19% CEA >200 ng/mL. Bone metastases developed in 21 patients; 67% had baseline LDH value >200 U/L, 33% KRAS MUT, and 19% CEA >200 ng/mL. Nine patients who developed brain metastases with KRAS MUT in 33% and baseline LDH >200 U/L in 33%.
| DISCUSSION
Colorectal cancer remains a leading cause of cancer related mortality worldwide, predominantly due to the development of liver metastases, which occurs in over 50% of patients. Multiple studies have been performed evaluating prognostic and predictive biomarkers to guide therapeutic decision-making. [17] [18] [19] [20] [21] Baseline serum CEA value, baseline serum LDH level, and tumoral KRAS mutation status have each been assessed as proposed biomarkers. However, this study predated the era of KRAS testing and thus, to our knowledge, our study is the first to address the relationship and interdependence between these three biomarkers.
Our study includes patients with unresectable colorectal liver metastases who had known KRAS status and baseline LDH and CEA values and who underwent treatment with HAI plus systemic chemotherapy. Patients were analyzed in two separate subgroups:
those patients with hepatic-only disease at baseline and those with extra-hepatic disease prior to commencement of HAI.
In patients with hepatic-only disease, KRAS, and LDH levels KRAS WT patients with baseline LDH ≤200 had a superior OS (P = 0.021). Elevated LDH was the only biomarker found to influence PFS. Baseline LDH >200 U/L remained significant after accounting for KRAS status, prior chemotherapy, and complete hepatic resection.
In the patient subgroup with extra-hepatic disease (n = 72), baseline CEA and LDH were important. In the multivariate model, LDH >200 U/L negatively impacted OS while there was only borderline significance in terms of CEA >200 ng/mL. In terms of PFS, an elevated CEA was the only influential biomarker.
We assessed patterns of tumor progression in the patient group with hepatic-only disease (n = 121). The two most common sites of tumor progression were lung and lymph nodes at 52.9% and 49.6%, respectively. Among the subset of patients with lung metastases, a high proportion (64.1%) had an elevated baseline LDH >200 U/L.
It is important to acknowledge limitations of our study based on the small sample size and single institution design. For example, CEA >200 ng/mL was not significantly associated with OS in our patient group, even though medical survival was 60 months versus 33 months for CEA ≤200 versus >200 ng/mL, respectively. Previous studies have reported the influence of CEA on survival in colorectal cancer and results from our study may have been limited by the small sample size.
| CONCLUSIONS
Our study shows that elevated serum levels of LDH at baseline significantly correlate with a poor prognosis in unresectable colorectal liver metastases. Other investigators have also shown LDH is a strong factor. 11 While serum CEA is the most commonly performed serum tumor marker in this patient population, our study validates the additional importance of serum LDH. The interrelationship between serum LDH and KRAS status is significant in terms of prognostication in patients with hepatic-only disease. Results from this study suggest that the incorporation of routine evaluation of serum CEA, serum LDH, and KRAS mutational status is merited to direct clinical decision making in this patient population. 
